In the Media

Prof. Tyler Jacks, president of the nonprofit Break Through Cancer, speaks to The New York Times’ Gina Kolata about his research on resistance to the drug daraxonrasib in pancreatic cancer patients. “We all believe that daraxonrasib and other KRAS inhibitors are important initial steps [for treating pancreatic cancer],” says Jacks. In the future, the research will lead to, “one day, cures.”